Target intelligence / Profile preview

Gram-negative bacterial cell membrane glycans and proteins

Molecular classification
Other
01

Overview

The Gram-negative bacterial cell membrane is a complex structure characterized by an outer membrane containing lipopolysaccharides (LPS), various glycans, and integral outer membrane proteins (OMPs). This surface serves as a critical barrier against environmental threats and host immune defenses, while also facilitating nutrient transport and cell signaling. In the context of immunotherapy, these surface components are targeted by bifunctional antibody-recruiting molecules (ARMs) or Alphamers. These therapeutic agents consist of a targeting domain that binds to bacterial membrane glycans or proteins and an effector domain that recruits endogenous host antibodies, such as polyclonal IgG or anti-alpha-Gal antibodies. By coating the bacterial surface with host antibodies, these drugs trigger potent immune effector mechanisms, including complement-dependent cytotoxicity (CDC) and antibody-dependent cellular phagocytosis (ADCP), leading to the rapid clearance of even multidrug-resistant (MDR) pathogens.

Other names
Gram-negative bacterial cell envelopeGram-negative outer membraneLipopolysaccharide (LPS)Outer membrane proteins (OMPs)Bacterial surface glycans
02

Mechanism of action

Recruitment of endogenous host antibodies (e.g., anti-alpha-Gal IgG) to the bacterial surface to induce opsonization, complement activation, and phagocytosis.

03

Biological functions

Cell wall organizationImmune responsePathogenesisMembrane permeability
04

Disease associations

InfectionSepsisPneumoniaUrinary tract infection
05

Safety considerations

Off-target effects on the host microbiomePotential for systemic inflammatory response (cytokine storm) due to rapid bacterial lysisEndotoxin release (LPS) during bacterial cell deathVariability in endogenous antibody titers among patients
06

Interacting drugs

CTX-09

3 more in the full profile.

07

Biomarkers

Anti-alpha-Gal antibody titersBacterial load (CFU/mL)C-reactive protein (CRP)ProcalcitoninComplement activation products (e.g., C3a, C5a)

Beyond the preview

Go deeper on Gram-negative bacterial cell membrane glycans and proteins.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gram-negative bacterial cell membrane glycans and proteins.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call